IL-1R2: A Potential Drug Target and Biomarker (G7850)

Target Name: IL1R2

NCBI ID: G7850

IL1R2

IL-1R2: A Potential Drug Target and Biomarker

Interleukin-1 (IL-1) is a cytokine that plays a crucial role in the regulation of immune and inflammatory responses. The IL-1 receptor, also known as type 2, is a protein that is expressed in various tissues and cells, including immune cells, endothelial cells, and epithelial cells. The IL-1 receptor is involved in the regulation of immune cell function, inflammation, and pain perception. In this article, we will discuss the potential drug target and biomarker for IL-1 receptor type 2, focusing on the biology and clinical applications of this protein.

IL-1 Receptor Type 2: Structure and Function

The IL-1 receptor is a cytokine receptor that is composed of an extracellular domain, a transmembrane region, and an intracellular domain. The extracellular domain consists of a N-terminus that is involved in the formation of a complex with other cytokines. The transmembrane region consists of a variable region and a constant region. The variable region includes the IL-1 receptor alpha chain, which is the portion of the receptor that is involved in the interaction with cytokines. The constant region includes the IL-1 receptor beta chain , which is the portion of the receptor that is involved in the interaction with the cytokine.

The IL-1 receptor is involved in the regulation of cellular processes such as cell growth, differentiation, and survival. It is also involved in the regulation of immune cell function, inflammation, and pain perception. The IL-1 receptor is activated by cytokines such as IL-1, which is produced by various cell types in response to an infection or injury.

IL-1 Receptor Type 2: Expression and Regulation

The IL-1 receptor is expressed in various tissues and cells, including immune cells, endothelial cells, and epithelial cells. It is involved in the regulation of immune cell function, inflammation, and pain perception. The IL-1 receptor is regulated by various enzymes and factors, including but not limited to post-transcriptional modifications, phosphorylation, ubiquitination, proteases, etc.

In clinical applications, IL-1 receptor antagonists are widely used to treat various inflammatory diseases, such as rheumatoid arthritis, osteoarthritis, and inflammatory bowel disease. In addition, IL-1 receptor antagonists are also used as immunotherapeutic drugs in tumor and cancer treatment.

IL-1 Receptor Type 2: Biology and Clinical Applications

In inflammatory diseases, IL-1 receptor antagonists are widely used. For example, metoclopramide is an antipsychotic drug that is also used to treat rheumatoid arthritis and other inflammatory diseases. Metoclopramide exerts its effects by inhibiting dopamine receptors in the central nervous system, thereby reducing symptoms of inflammation.

In tumors and cancer treatment, IL-1 receptor antagonists are also widely used. For example, the IL-1 receptor antagonist paclitaxel is used to treat a variety of cancers, including ovarian cancer, breast cancer, and lung cancer. Paclitaxel inhibits the growth and spread of tumor cells by inhibiting IL-1 receptors.

In addition, IL-1 receptor antagonists are also used to treat other diseases, such as pain and inflammatory bowel disease.

IL-1 Receptor Type 2: Future Development

With the continuous development of science and technology, the research on IL-1 receptor has gradually deepened. In the future, research on IL-1 receptor antagonists will mainly focus on the following aspects:

1. Molecular mechanism: In-depth study of the mechanism of action of IL-1 receptor antagonists, including how they bind to IL-1 receptors and how they regulate the function of IL-1 receptors.

2. Clinical application: Study the application of IL-1 receptor antagonists in the treatment of inflammatory diseases and tumors, as well as their dosage, treatment duration and side effects.

3. Biomarkers: Study the biological properties of IL-1 receptor antagonists

Protein Name: Interleukin 1 Receptor Type 2

Functions: Non-signaling receptor for IL1A, IL1B and IL1RN. Reduces IL1B activities. Serves as a decoy receptor by competitive binding to IL1B and preventing its binding to IL1R1. Also modulates cellular response through non-signaling association with IL1RAP after binding to IL1B. IL1R2 (membrane and secreted forms) preferentially binds IL1B and poorly IL1A and IL1RN. The secreted IL1R2 recruits secreted IL1RAP with high affinity; this complex formation may be the dominant mechanism for neutralization of IL1B by secreted/soluble receptors

The "IL1R2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IL1R2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets